| Literature DB >> 32527043 |
Yu-Chin Lien1,2, Paul Zhiping Wang3, Xueqing Maggie Lu3, Rebecca A Simmons1,2.
Abstract
Intrauterine growth retardation (IUGR), which induces epigenetic modifications and permanent changes in gene expression, has been associated with the development of type 2 diabetes. Using a rat model of IUGR, we performed ChIP-Seq to identify and map genome-wide histone modifications and gene dysregulation in islets from 2- and 10-week rats. IUGR induced significant changes in the enrichment of H3K4me3, H3K27me3, and H3K27Ac marks in both 2-wk and 10-wk islets, which were correlated with expression changes of multiple genes critical for islet function in IUGR islets. ChIP-Seq analysis showed that IUGR-induced histone mark changes were enriched at critical transcription factor binding motifs, such as C/EBPs, Ets1, Bcl6, Thrb, Ebf1, Sox9, and Mitf. These transcription factors were also identified as top upstream regulators in our previously published transcriptome study. In addition, our ChIP-seq data revealed more than 1000 potential bivalent genes as identified by enrichment of both H3K4me3 and H3K27me3. The poised state of many potential bivalent genes was altered by IUGR, particularly Acod1, Fgf21, Serpina11, Cdh16, Lrrc27, and Lrrc66, key islet genes. Collectively, our findings suggest alterations of histone modification in key transcription factors and genes that may contribute to long-term gene dysregulation and an abnormal islet phenotype in IUGR rats.Entities:
Keywords: ChIP-Seq; bivalent gene; epigenetics; histone modifications; intrauterine growth restriction; islets; transcription factor binding motif
Mesh:
Substances:
Year: 2020 PMID: 32527043 PMCID: PMC7348746 DOI: 10.3390/cells9061435
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Principal components analysis of histone modifications in islets demonstrates that the three histone marks clearly separate. The X-axis (Comp1) represents 53% of the variability between samples and the Y-axis (Comp 2) represents 14% of the variability between samples.
Figure 2Genomic locations of histone modifications. Bars represent the location and proportion of each histone mark, TSS defined as 100 bp upstream to 1 kb downstream of TSS. Promoter-TSS is 1 kb upstream to 100 bp downstream of TSS. 5′ untranslated region (5 ‘UTR) starts at TTS and ends before the initiation codon. 3′ UTR starts immediately following termination codon. Non-coding regions are non-encoding protein sequences. Intergenic regions represent regions beyond the above defined regions.
Figure 3Transcription start site plots (TSS plots) of histone modifications showing the distribution and enrichment of each histone mark. (a–c) represents H3K4me3, H3K27me3, and H3K27Ac marks in 2-wk islets, respectively. (d–f) represents H3K4me3, H3K27me3, and H3K27Ac mark in 10-wk islets, respectively. Peak input/enrichment shown on vertical axes and position base-pair shown on horizontal axes. Red lines indicate control islets and blue lines indicate IUGR islets.
The number of genes potentially regulated by histone modifications.
|
|
| |||||
|---|---|---|---|---|---|---|
| Histone Mark | Total Gene # | Up-Regulated Gene # | Down-Regulated Gene # | Total Gene # | Up-Regulated Gene # | Down-Regulated Gene # |
|
| 41 | 29 | 12 | 638 | 344 | 294 |
|
| 61 | 23 | 38 | 357 | 24 | 333 |
|
| 148 | 52 | 96 | 401 | 29 | 372 |
|
| 0 | 0 | 0 | 6 | 3 | 3 |
Genes potentially regulated by all 3 marks.
| Gene | Gene Name | H3K4me3 | H3K27me3 | H3K27Ac | RNASeq | RNASeq |
|---|---|---|---|---|---|---|
|
| transient receptor potential cation channel, subfamily M, member 5 | 1.27 | −0.78 | 0.96 | 0.8302 | 0.0215 |
|
| transcription factor A, mitochondrial | 0.90 | −0.95 | 1.10 | 0.5014 | 0.0148 |
|
| MCF.2 cell line derived transforming sequence-like | 1.17 | −1.06 | 1.19 | 0.4669 | 0.0500 |
|
| solute carrier family 28 member 2 | −1.05 | 1.77 | −0.75 | −1.2177 | 0.0040 |
|
| tumor necrosis factor | −1.47 | 1.01 | −0.95 | −2.1019 | 0.0020 |
|
| myelin protein zero | −0.55 | 0.42 | −0.56 | −2.4936 | 0.0027 |
Differentially expressed genes with persistent changes for H3K27Ac histone mark.
| 2-wk Islets | 10-wk Islets | |||||
|---|---|---|---|---|---|---|
| Genes | RNAseq | RNAseq | H3K27Ac | RNAseq | RNAseq | H3K27Ac |
|
| −1.08 | 1.30 × 10−2 | −0.98 | −1.37 | 1.74 × 10−4 | −0.88 |
|
| −2.12 | 8.77 × 10−5 | −0.66 | −1.42 | 5.75 × 10−3 | −0.48 |
|
| −0.99 | 1.14 × 10−2 | −0.63 | −0.78 | 3.54 × 10−2 | −0.56 |
|
| −1.42 | 1.41 × 10−3 | −0.12 | −1.92 | 5.29 × 10−7 | −0.76 |
|
| −0.98 | 3.16 × 10−2 | −0.67 | −0.92 | 2.37 × 10−2 | −0.47 |
|
| −1.39 | 2.83 × 10−4 | −0.59 | −0.91 | 1.67 × 10−2 | −0.77 |
|
| −1.10 | 2.69 × 10−4 | −0.56 | −0.83 | 4.53 × 10−3 | −0.77 |
|
| −1.36 | 5.15 × 10−5 | −0.06 | −1.97 | 7.32 × 10−11 | −0.74 |
|
| −1.85 | 1.82 × 10−4 | −0.87 | −1.18 | 2.05 × 10−2 | −0.82 |
|
| −0.92 | 4.49 × 10−2 | −0.41 | −1.48 | 2.62 × 10−5 | −0.47 |
|
| −2.10 | 3.54 × 10−3 | −0.33 | −1.93 | 2.48 × 10−2 | −1.35 |
|
| −1.15 | 1.39 × 10−2 | −0.28 | −1.97 | 1.32 × 10−7 | −0.56 |
|
| −1.03 | 1.17 × 10−3 | −0.64 | −1.37 | 9.37 × 10−7 | −0.48 |
|
| −1.61 | 3.84 × 10−3 | −0.38 | −1.86 | 9.29 × 10−5 | −0.95 |
|
| −1.42 | 2.34 × 10−3 | −0.51 | −0.97 | 3.91 × 10−2 | −0.90 |
|
| −0.61 | 3.89 × 10−2 | −0.55 | −0.59 | 2.96 × 10−2 | −0.59 |
|
| −1.26 | 1.41 × 10−2 | −0.14 | −3.13 | 9.28 × 10−14 | −0.54 |
|
| −1.03 | 2.87 × 10−5 | −0.41 | −0.70 | 4.26 × 10−3 | −0.66 |
|
| −0.92 | 2.98 × 10−3 | −1.01 | −0.90 | 1.26 × 10−3 | −0.51 |
|
| −1.14 | 1.64 × 10−2 | −0.56 | −1.16 | 4.90 × 10−3 | −0.84 |
Top IPA pathways potentially regulated by histone modifications and disrupted in 10-wk IUGR islets.
| Histone Mark | Ingenuity Canonical Pathways | |
|---|---|---|
| H3K4me3 | Type II Diabetes Mellitus signaling | 1.32 × 10−4 |
| antiproliferative role of TOB in T- cell signaling | 7.24 × 10−4 | |
| Tight junction signaling | 1.00 × 10−3 | |
| RAR activation | 1.12 × 10−3 | |
| PI3K signaling in B lymphocytes | 1.23 × 10−3 | |
| Factors promoting cardiogenesis in vertebrates | 1.23 × 10−3 | |
| BMP signaling pathway | 1.41 × 10−3 | |
| Neurotrophin/TRK signaling | 1.51 × 10−3 | |
| PPAR signaling | 1.55 × 10−3 | |
| H3K27me3 | Cellular stress and injury | 2.24 × 10−7 |
| Hepatic fibrosis / hepatic stellate cell activation | 1.41 × 10−6 | |
| cAMP-mediated signaling | 1.32 × 10−5 | |
| Macrophage function | 2.95 × 10−5 | |
| Mitochondrial function / Autophagy | 3.55 × 10−5 | |
| Citrulline-nitric oxide cycle | 3.63 × 10−5 | |
| Wnt/β-catenin signaling | 8.13 × 10−5 | |
| Axonal guidance signaling | 9.12 × 10−5 | |
| eNOS signaling | 3.63 × 10−4 | |
| H3K27Ac | Polyamine regulation | 1.78 × 10−6 |
| Cell migration signaling | 1.02 × 10−5 | |
| Production of nitric oxide and reactive oxygen species in Macrophages | 1.05 × 10−5 | |
| IL-9 signaling | 1.35 × 10−5 | |
| PDGF signaling | 3.24 × 10−5 | |
| PPAR signaling | 4.90 × 10−5 | |
| Unfolded protein response | 5.13 × 10−5 | |
| ERK/MAPK signaling | 6.46 × 10−5 | |
| Phospholipase C signaling | 1.12 × 10−4 |
Figure 4Transcription factor binding motifs enriched in islets at 2 weeks of age. (a) H3K4me3; (b) H3K27me3.
Figure 5Transcription factor binding motifs enriched in islets at 10 weeks of age. (a) H3K4me3; (b) H3K27me3.
Transcription factor binding motifs with persistent histone modification changes.
| H3K4me3 | |||||
|---|---|---|---|---|---|
| Motif Name | Consensus | 2w_IUGR | 2w_Ctrl | 10w_IUGR | 10w_Ctrl |
| ELF3 | ANCAGGAAGT | 1.00 × 10−43 | 0.1 | 1.00 × 10−9 | 1 |
| ELF5 | ACVAGGAAGT | 1.00 × 10−34 | 0.1 | 1.00 × 10−7 | 1 |
| ERG | ACAGGAAGTG | 1.00 × 10−71 | 0.1 | 1.00 × 10−8 | 1 |
| ETS1 | ACAGGAAGTG | 1.00 × 10−48 | 1 | 1.00 × 10−16 | 0.1 |
| ETV1 | AACCGGAAGT | 1.00 × 10−80 | 0.1 | 1.00 × 10−11 | 1 |
| ETV2 | NNAYTTCCTGHN | 1.00 × 10−62 | 1 | 1.00 × 10−9 | 0.1 |
| EWS:ERG | ATTTCCTGTN | 1.00 × 10−69 | 0.1 | 1.00 × 10−8 | 1 |
| GABPA | RACCGGAAGT | 1.00 × 10−58 | 0.1 | 1.00 × 10−8 | 0.1 |
| SMAD4 | VBSYGTCTGG | 1.00 × 10−24 | 1 | 1.00 × 10−6 | 1 |
|
| |||||
|
|
|
|
|
|
|
| MEIS1 | VGCTGWCAVB | 1 | 1.00 × 10−4 | 1 | 1.00 × 10−17 |
| PR | VAGRACAKNCTGTBC | 0.1 | 1.00 × 10−11 | 1 | 1.00 × 10−20 |
| OLIG2 | RCCATMTGTT | 1 | 1.00 × 10−5 | 0.1 | 1.00 × 10−10 |
Critical upstream regulators identified in transcriptome datasets.
| 2-wk | |||
|---|---|---|---|
| Upstream Regulator | Activation | Target Gene Number | |
| FOXL2 | 2.06 | 7.02 × 10−3 | 7 |
| ELK1 | 0.74 | 1.77 × 10−3 | 7 |
| ETS1 | 0.36 | 1.65 × 10−2 | 14 |
| NKX2-5 | −0.39 | 4.13 × 10−2 | 4 |
| BCL6 | −1.24 | 5.37 × 10−3 | 12 |
| CEBPA | 1.89 | 1.87 × 10−7 | 37 |
| CEBPB | 2.73 | 1.94 × 10−7 | 36 |
| PAX7 | 1.14 | 8.16 × 10−4 | 9 |
| SOX4 | 1.89 | 5.68 × 10−4 | 16 |
| HNF1B | −1.63 | 5.26 × 10−5 | 14 |
|
| |||
|
|
|
|
|
| FLI1 | 0.45 | 5.42 × 10−4 | 14 |
| CDX2 | −0.84 | 1.29 × 10−4 | 26 |
| SOX10 | −0.84 | 1.80 × 10−6 | 13 |
| EBF1 | −1.23 | 1.09 × 10−5 | 30 |
| SOX9 | −0.43 | 3.72 × 10−2 | 11 |
| MITF | −3.25 | 8.96 × 10−4 | 39 |
| NANOG | −0.24 | 2.62 × 10−3 | 22 |
| TCF | −2.00 | 9.48 × 10−8 | 27 |
| THRB | 0.42 | 2.38 × 10−8 | 47 |
| ELF3 | −2.07 | 5.52 × 10−3 | 8 |
| ERG | −4.45 | 1.40 × 10−10 | 50 |
Potential bivalent genes critical for long-term IUGR phenotype.
| Gene | Gene Name | Bivalency | |||
|---|---|---|---|---|---|
| 2-wk | 10-wk | ||||
| Control | IUGR | Control | IUGR | ||
|
| aconitate decarboxylase 1 | + | + |
| + |
|
| fibroblast growth factor 21 | + | + |
| + |
|
| serpin family A member 11 | + | + |
| + |
|
| cadherin 16 |
|
| + |
|
|
| leucine-rich repeat-containing 27 |
|
| + |
|
|
| leucine-rich repeat-containing 66 |
|
| + |
|